J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

(Reuters) - British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour.

In a report released today, Florent Cespedes from Bernstein maintained a Buy rating on GlaxoSmithKline (GSK – Research Report), with a price target of £23.55. The company’s shares closed ...

A high-profile team of architects, landscape designers, and consultants has been appointed to progress a masterplan for the redevelopment of the former GSK headquarters at 980 Great West Road, ...

Last month saw a number of alliances forming in a range of therapeutic spaces but there has been one serial collaborator that stands out – GSK. The British pharma giant seems to have embarked on a ...